A phase I RCT of 2-deoxyglucose has been designed [119] and mTOR inhibitors sirolimus and everolimus have been tested in human ADPKD RCTs [120,121,122]. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.